Technical Platform of Innovative Oncolytic Drugs Targeting Tumor Metabolism

Based on the characteristics of abnormal tumor metabolism, the platform adopts the existing bacterial delivery system to carry and encode active target molecules consuming tumor cell-dependent nutrients to precisely target the tumor and consume tumor cell-dependent nutrients. The platform is capable of basic research on tumor metabolism, as well as designing, screening and optimization of target genes, screening and construction of plasmid vectors, target protein expression and activity identification, and construction of tumor-targeted oncolytic bacteria drugs.

[1]Front. Cell Dev. Biol., 12 January 2021 | https://doi.org/10.3389/fcell.2020.603837
[2]Trends Endocrinol Metab. 2021 Jun;32(6):367-381.

The company was established in Guangzhou as a R&D biopharmaceutical company in July 2016

We have built a research system from lab scale to pilot scale, including low-temperature cold storage room, pilot plant, QC testing room, R&D laboratory, etc. The platform is intended for the development of original genetic engineering drugs, upstream and downstream research and development of products, and the development of core technologies for pilot- and large-scale production. In addition to carrying out research and development of our own varieties, the platform can also undertake external business such as genetic engineering drug technology development and process research, process validation, and quality control, and stability development techniques of biological products.

[1]Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis[J]. Cancer Research, 2007, 67(7):3201-3209.
[2] Biopharmaceutical Drug Development Pillars: Begin With the End in Mind .Clin Pharmacol Ther. 2019 Jan;105(1):33-35.

Technical Platform for Research on Tumor-targeting Mechanism of Oncolytic Bacteria

Bacterial therapy for tumor is one of the most concerned antitumor therapies at present. It is extremely important to investigate and determine the tumor-targeting mechanism of oncolytic bacteria for tumor treatment. We have constructed a technical platform for research on tumor-targeting mechanism of oncolytic bacteria in terms of tumor immunity, tumor vascular distribution, and bacterial chemotaxis mechanism, and in combination with flow cytometry, genome sequencing, protein immunoblotting, ELISA, bioinformatics analysis, and other technologies. With the help of this platform, the tumor-targeting and -colonization mechanism of oncolytic bacteria will be further investigated, providing a theoretical basis for the research and development of safe, effective, and highly targeted oncolytic bacteria.

[1] Ze Mi, Zhi-Chao Feng, et al. Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy[J].Journal Of Cancer, 2019; 10(20): 4765–4776.
[2]Shibin, Zhou, Claudia, et al. Tumour-targeting bacteria engineered to fight cancer[J]. Nature reviews. Cancer, 2018.

Technical Platform for In Vitro and In Vivo Pharmacodynamic Evaluation of Antitumor Drugs

We have established a technical platform for preclinical pharmacodynamic evaluation of antitumor drugs at different levels of molecules, cells, and animals. The platform is designed to evaluate tumor angiogenesis, tumor metastasis, tumor immunity, cell cycle arrest, tumor drug resistance, tumor cell apoptosis, etc. in each link of tumorigenesis, proliferation, growth, and metastasis. By combining in vivo imaging technology and applied genomics with proteomics technology, we have established experimental models based on novel pharmacodynamics and human disease pathogenesis, including the establishment of a tumor cell bank and various tumor-bearing animal models, e.g., nude mouse model for human hepatocellular carcinoma cell line HCCLM3, nude mouse model for human small cell lung cancer cell line A549, nude mouse model for human small cell lines H446 and H69, nude mouse model for human cervical cancer cell line Hela, nude mouse model for human breast cancer cell line MDA-MB-231, nude mouse model for human glioblastoma in situ cell line U87, nude mouse model for human pancreatic cancer cell line CFPAC-1, mouse model for lymphocytic leukemia cell line L1210, mouse model for primary acute leukemia, mouse model for Lewis lung cancer, B16 melanoma model, mouse 4T1 breast cancer model, mouse model for PyMT-induced breast cancer in situ, patient-derived organoid (PDO) model, and human-derived tumor xenograft (PDX) model, and mastered the techniques of new targets and pharmacodynamic evaluation for the research and development of innovative drugs.